The document provides information about the Tamil Nadu Medical Services Corporation Limited (TNMSC), which supports government medical institutions in Tamil Nadu by procuring and distributing high quality drugs, medicines, surgical items and sutures. Some key details:
1) TNMSC was incorporated in 1994 and started operations in 1995, procuring drugs through a centralized tender process to ensure quality and competitive rates.
2) It serves over 11,000 government medical facilities across Tamil Nadu, including hospitals, primary health centers and veterinary institutions.
3) TNMSC's annual procurement is over Rs. 12,000 lakhs covering 271 drug items, 92 suture items and 63 surgical items. Rates have reduced
Background: Pharmacy developed as a profession over several decades with the advent of apothecaries and was formalized as a profession and regulated in India beginning 1948 with the Pharmacy Act. Public health, existent for centuries was only formalized in India in 1987 through the Model Public Health act. Clinical pharmacy through structured and formalized PharmD education is fairly new to 21st century India. Clinical pharmacists play a very important role in promoting public health through various initiatives – health education, health communication, medication review, medication adherence to name a few. There is however, little recognition for clinical pharmacists as public health professionals even in developed countries where public health and pharmacy systems have co-existed for decades. In India, as both fields emerge, it is important to find synergies and open up pathways for collaboration and cooperation to ensure a stronger pool of public health field clinicians, researchers and professionals.
This session will focus on identifying the roles of public health pharmacists with focus on areas of convergence and models for collaboration and cooperation between public health and pharmacy professionals.
Session aim: Discuss strategies to enhance capacity of pharmacists to advance public health outcomes.
Session objectives: At the end of this session, participants will be able to:
• Explain how pharmacists can play pivotal roles in disease prevention and health promotion
• Identify key interdisciplinary approaches where pharmacists can help achieve optimal public health outcomes
• Discuss strategies to integrate public health practice into pharmacological training and pharmaceutical care.
Content: Throughout the world, pharmacy as a profession is evolving. In recent years, several entities involved in pharmacy education have identified public health as a major area for improvement and expansion within the core pharmacy education. Pharmacists have been identified as key healthcare professionals in achieving health goals as mentioned in Healthy People 2020. In order to successfully integrate pharmacists as public health professionals, there is a need to introduce the principles and concepts of public health early on in pharmacy education. It is equally important to create and develop opportunities for practicing pharmacists and demonstrate the impact of pharmacists toward improving the population’s health. In this session, targeted interventions to outcomes assessment, differences and similarities will be discussed with implications for effectively advancing the capacity of pharmacists to achieve public health outcomes.
References
1. Policy Statement: The Role of the Pharmacist in Public Health. Policy Number 200614. American Public Health Association. November 8, 2006.
2. Capper, SA, Sands, CD. The Vital Relationship Between Public Health and Pharmacy. The International Journal of Pharmacy Education. Fall 2006, Issue 2.
The document discusses the Clinical Establishments Act passed by the Indian Parliament in 2010. The key objectives of the act are to prevent quackery by introducing mandatory registration of clinical establishments, establish digital registries of establishments, and improve healthcare quality by prescribing minimum standards. It defines what constitutes a clinical establishment, discusses the authorities and responsibilities established at the national and state levels, and outlines penalties for non-compliance. It also provides details on the minimum standards for basic clinical establishments.
The document provides an overview of regulatory affairs. It discusses the historical development of regulation, including key events that led to increased regulation of drugs and medical products. It also outlines the roles and responsibilities of regulatory affairs departments and professionals in submitting information and ensuring compliance with regulations from agencies like the FDA to obtain approval to market products. The goal of regulatory affairs is to protect public health by ensuring safety, efficacy and quality of drugs and other medical products.
Operational Planning of Hospitals towards COVID 19 Pandemic- Indian PerspectiveLallu Joseph
This presentation is about the preparation of Indian Hospitals towards managing patients during the COVID 19 Pandemic. This is based on experience shared by hospitals for the benefit of other hospitals to prepare themselves. How to set up the Hospital Incident Command System, components of managing the pandemic like infection control, Engineering Controls, Patient flow and Triaging, Supply chain management including PPE, Clinical management, Manpower management and shifts, Training.
Pharmaceutical Supply Chain Integrity and Security (2016)Arete-Zoe, LLC
The course material serves many interests by facilitating understanding of environment, dynamics, and influences affecting regulatory policies and corporate decision-making that ultimately determine access, availability, and safety of pharmaceutical products. In the first four chapters, we will introduce and describe the regulatory environment in the United States, European Union, in major Asian economies such as Japan, India and China, regulatory policies in Russia, and international standards. Holistic understanding of regulatory environment in global context is essential for understanding of the challenges in pharmaceutical supply chain in the current globalized, inter-connected and inter-dependent economy. In chapter “Enforcement”, we will introduce national enforcement systems in the context of globally operating pharmaceutical industry, and present major initiatives and events. Industry trends such as consolidation, outsourcing of key operations, and shift of manufacturing to Asia determine operational environment. Limited sourcing options, and increasing complexity and distance, affect vulnerability to disruption. Track and trace requirements introduced new vulnerabilities especially in the information management domain.
Law Related to Governing the Commissioning of Hospital
Laws Governing the Qualifications / Practice and Conduct of Professionals
Law Governing Storage / Sale of Drugs and Safe Medication
Law Governing Biomedical Research
Law Governing to Management of Patients
Law Governing Medico Legal Aspects
Law Governing The Safety of Patients, Public and Staff within the Hospital Premises and Environmental Protection
Law Governing the Safety of Patients, Public and Staff within the Hospital Premises
Laws Governing the Employment of Manpower
Law Governing to Professional Training and Research
Regulations Governing the Business Aspects of Hospital
The document provides an overview of drug regulation systems in India, the United States, and other countries. It discusses the key functions of drug regulatory agencies, which include product registration, regulating drug manufacturing and distribution, monitoring drug safety and efficacy, and regulating drug promotion and information. The main regulatory bodies in India are the Central Drugs Standard Control Organization and other organizations like the Indian Council of Medical Research. In the US, the main regulatory agency is the Food and Drug Administration, which aims to promote health by reviewing research and ensuring drugs are safe. The document also discusses regulatory agencies in other countries like Japan.
Background: Pharmacy developed as a profession over several decades with the advent of apothecaries and was formalized as a profession and regulated in India beginning 1948 with the Pharmacy Act. Public health, existent for centuries was only formalized in India in 1987 through the Model Public Health act. Clinical pharmacy through structured and formalized PharmD education is fairly new to 21st century India. Clinical pharmacists play a very important role in promoting public health through various initiatives – health education, health communication, medication review, medication adherence to name a few. There is however, little recognition for clinical pharmacists as public health professionals even in developed countries where public health and pharmacy systems have co-existed for decades. In India, as both fields emerge, it is important to find synergies and open up pathways for collaboration and cooperation to ensure a stronger pool of public health field clinicians, researchers and professionals.
This session will focus on identifying the roles of public health pharmacists with focus on areas of convergence and models for collaboration and cooperation between public health and pharmacy professionals.
Session aim: Discuss strategies to enhance capacity of pharmacists to advance public health outcomes.
Session objectives: At the end of this session, participants will be able to:
• Explain how pharmacists can play pivotal roles in disease prevention and health promotion
• Identify key interdisciplinary approaches where pharmacists can help achieve optimal public health outcomes
• Discuss strategies to integrate public health practice into pharmacological training and pharmaceutical care.
Content: Throughout the world, pharmacy as a profession is evolving. In recent years, several entities involved in pharmacy education have identified public health as a major area for improvement and expansion within the core pharmacy education. Pharmacists have been identified as key healthcare professionals in achieving health goals as mentioned in Healthy People 2020. In order to successfully integrate pharmacists as public health professionals, there is a need to introduce the principles and concepts of public health early on in pharmacy education. It is equally important to create and develop opportunities for practicing pharmacists and demonstrate the impact of pharmacists toward improving the population’s health. In this session, targeted interventions to outcomes assessment, differences and similarities will be discussed with implications for effectively advancing the capacity of pharmacists to achieve public health outcomes.
References
1. Policy Statement: The Role of the Pharmacist in Public Health. Policy Number 200614. American Public Health Association. November 8, 2006.
2. Capper, SA, Sands, CD. The Vital Relationship Between Public Health and Pharmacy. The International Journal of Pharmacy Education. Fall 2006, Issue 2.
The document discusses the Clinical Establishments Act passed by the Indian Parliament in 2010. The key objectives of the act are to prevent quackery by introducing mandatory registration of clinical establishments, establish digital registries of establishments, and improve healthcare quality by prescribing minimum standards. It defines what constitutes a clinical establishment, discusses the authorities and responsibilities established at the national and state levels, and outlines penalties for non-compliance. It also provides details on the minimum standards for basic clinical establishments.
The document provides an overview of regulatory affairs. It discusses the historical development of regulation, including key events that led to increased regulation of drugs and medical products. It also outlines the roles and responsibilities of regulatory affairs departments and professionals in submitting information and ensuring compliance with regulations from agencies like the FDA to obtain approval to market products. The goal of regulatory affairs is to protect public health by ensuring safety, efficacy and quality of drugs and other medical products.
Operational Planning of Hospitals towards COVID 19 Pandemic- Indian PerspectiveLallu Joseph
This presentation is about the preparation of Indian Hospitals towards managing patients during the COVID 19 Pandemic. This is based on experience shared by hospitals for the benefit of other hospitals to prepare themselves. How to set up the Hospital Incident Command System, components of managing the pandemic like infection control, Engineering Controls, Patient flow and Triaging, Supply chain management including PPE, Clinical management, Manpower management and shifts, Training.
Pharmaceutical Supply Chain Integrity and Security (2016)Arete-Zoe, LLC
The course material serves many interests by facilitating understanding of environment, dynamics, and influences affecting regulatory policies and corporate decision-making that ultimately determine access, availability, and safety of pharmaceutical products. In the first four chapters, we will introduce and describe the regulatory environment in the United States, European Union, in major Asian economies such as Japan, India and China, regulatory policies in Russia, and international standards. Holistic understanding of regulatory environment in global context is essential for understanding of the challenges in pharmaceutical supply chain in the current globalized, inter-connected and inter-dependent economy. In chapter “Enforcement”, we will introduce national enforcement systems in the context of globally operating pharmaceutical industry, and present major initiatives and events. Industry trends such as consolidation, outsourcing of key operations, and shift of manufacturing to Asia determine operational environment. Limited sourcing options, and increasing complexity and distance, affect vulnerability to disruption. Track and trace requirements introduced new vulnerabilities especially in the information management domain.
Law Related to Governing the Commissioning of Hospital
Laws Governing the Qualifications / Practice and Conduct of Professionals
Law Governing Storage / Sale of Drugs and Safe Medication
Law Governing Biomedical Research
Law Governing to Management of Patients
Law Governing Medico Legal Aspects
Law Governing The Safety of Patients, Public and Staff within the Hospital Premises and Environmental Protection
Law Governing the Safety of Patients, Public and Staff within the Hospital Premises
Laws Governing the Employment of Manpower
Law Governing to Professional Training and Research
Regulations Governing the Business Aspects of Hospital
The document provides an overview of drug regulation systems in India, the United States, and other countries. It discusses the key functions of drug regulatory agencies, which include product registration, regulating drug manufacturing and distribution, monitoring drug safety and efficacy, and regulating drug promotion and information. The main regulatory bodies in India are the Central Drugs Standard Control Organization and other organizations like the Indian Council of Medical Research. In the US, the main regulatory agency is the Food and Drug Administration, which aims to promote health by reviewing research and ensuring drugs are safe. The document also discusses regulatory agencies in other countries like Japan.
Ranbaxy is India's largest pharmaceutical company, producing generic medicines for over 125 countries. It was founded in 1961 and went public in 1973. Ranbaxy has a global footprint with manufacturing facilities in 8 countries and offices in 43 countries. In 2008, Ranbaxy entered an alliance with Daiichi Sankyo to create an innovator and generic pharmaceutical powerhouse, now ranking among the top 20 pharmaceutical companies globally. Ranbaxy's mission is to enrich lives globally with quality and affordable pharmaceuticals.
The Drugs and Cosmetics Act of 1940 and its subsequent amendments aim to regulate and ensure safety and quality of drugs and cosmetics in India. Key provisions include licensing requirements for import, manufacture, and sale of drugs and cosmetics. The act establishes regulatory bodies like the Drugs Technical Advisory Board and Drugs Control Committees. It defines terms like misbranded, adulterated, and spurious drugs and cosmetics. The schedules to the act and rules classify drugs based on their use and safety.
The document provides an overview of Japan's regulatory system for pharmaceutical products. It discusses the classification of medical products, the required licenses to manufacture and market products, and the roles of the Ministry of Health and Pharmaceuticals and Medical Devices Agency. It also summarizes regulations around clinical trials, marketing approval, pricing, manufacturing, advertising, packaging, patents, trademarks, and product liability.
Understanding the Medical device Single Audit Program (MDSAP) & How to Prepar...Greenlight Guru
The Medical Device Single Audit Program (MDSAP) is an international initiative spearheaded by the International Medical Device Regulatory Forum (IMDRF) to develop a standardized global approach to auditing and inspecting of medical device manufacturers that will be accepted by multiple regulators to address QMS/GMP requirements.
Although the program has seen relatively low participation to date, the promise to help reduce compliance cost for device makers by eliminating the need for multiple quality system audits and inspections means there is much to be gained by industry from a successful implementation the program.
This presentation will cover:
-Understand the goals and benefits of the MDSAP program
-What are the main differences between MDSAP and standard auditing
-How to benchmark your QMS against the MDSAP
-How the new non-conformance grading system works
-How to prepare your company for a successful MDSAP implementation
Watch the presentation here: https://www.greenlight.guru/webinar/medical-device-single-audit-program-mdsap
regulatory requirnment and approval procedure for drugs and cosmetics, medica...sandeep bansal
This document outlines the regulatory requirements and approval procedures for drugs, cosmetics, medical devices, biological products, herbal medicines, and foods/nutraceuticals in India. It discusses the key regulatory bodies like the Central Drugs Standard Control Organization (CDSCO) and the application processes. For drugs, the new drug approval procedure is described involving applying to the DCGI and undergoing clinical trials and reviews. For other products, the document explains the application forms and documents required for approval from bodies like FSSAI.
Este documento presenta el plan de estudios de la carrera de Técnico de Laboratorio Clínico, incluyendo las fechas y temas de las clases de Salud Pública durante el año 2013. Explica brevemente el rol del Técnico de Laboratorio y la importancia de estudiar Salud Pública en esta carrera. También resume la evolución histórica de los conceptos de salud y enfermedad, las funciones de la OMS y OPS, y las definiciones modernas de salud adoptadas por la OMS.
This presentation provides an overview of nutraceuticals, including definitions of key terms like nutraceuticals and dietary supplements. It discusses examples of nutraceutical products like vitamins, minerals, metabolites, herbs and proteins/amino acids. The presentation also outlines the competitive nutraceutical landscape and provides statistics on the size of the Indian nutraceutical industry, projected to reach $4.4 billion by 2023. It directs attendees to additional resources on nutraceuticals from the primaryinfo.com website.
Fundamental knowledge on pharmaceutical
product development and translation from laboratory to market.
Quality management systems: Quality management & Certifications.
Si x sigma concepts.
Aim of 6 sigma concepts.
Process of 6 sigma concepts.
The Clinical Establishments (Registration & Regulation) Act mithun kherdemithun.kherde
The document discusses the history and need for regulation of clinical establishments in India. It outlines key constitutional provisions related to public health and various laws enacted over time to regulate medical professionals and institutions. The Clinical Establishments Act of 2010 was enacted to address ongoing issues of inadequate oversight and create a uniform system for registration, minimum standards, and monitoring of all clinical establishments across India. The Act established mechanisms like the National and State Councils for Clinical Establishments and District Registering Authorities to classify, register, and ensure compliance of healthcare facilities.
The document outlines a presentation on Schedule Y, which regulates clinical trials in India. It discusses the history of drug regulation in India, the key provisions of Schedule Y, and recent amendments made to Schedule Y. Some of the major changes include new definitions for clinical trials and new drugs, as well as additional regulation for special patient populations and post-marketing surveillance. The presentation provides an overview of Schedule Y and the rules governing clinical research in India.
This document contains opinions from Dr. Rajive K. Dikshit on various healthcare bills and policies in India. Some key points:
1) It opposes the National Commission for Human Resources in Health Bill, arguing it will centralize power and remove autonomy of existing councils.
2) It argues mandatory rural service after internship should only apply to graduates of government colleges and be optional for private colleges.
3) It stresses the need to improve facilities and pay for doctors in rural areas to attract them, rather than force compulsory service.
This document discusses quality and accreditation in hospitals in India. It provides information on:
1) What NABH is and its organizational structure, including its technical committee, accreditation committee, appeals committee and secretariat.
2) NABH's accreditation standards, which have 10 chapters covering 102 standards and 636 objectives.
3) The NABH accreditation process, including self-assessment, pre-assessment, final assessment, and the criteria hospitals are assessed against.
4) Consequences for hospitals like inactive status, shifting renewal dates, abeyance, suspension and withdrawal of accreditation if they do not meet requirements.
This document provides a checklist of documents required for obtaining market authorization in various BRICS countries. It introduces BRICS as an emerging market comprising Brazil, Russia, India, China and South Africa. Reasons for the emergence of BRICS markets include declining growth in developed markets and availability of patient populations in emerging markets. The checklist then outlines the documents required for market authorization from the regulatory authorities in India, China, South Africa and other BRICS countries. These include application forms, composition details, clinical trial reports, GMP certificates, and other product-specific documents.
Dear Students
We can help you to write total dissertation/project report.
Our 9 step method of project writing:-
Step 1) Helping you in Selection of topic.
Step 2) Group discussion / conference call with in team of professors.
Step 3) Helping you in Preparation of Synopsis/ proposal & sent to project guide
The document discusses NABH (National Accreditation Board for Hospitals and Healthcare Providers), which sets standards for quality healthcare in India. It establishes that quality refers to how good or satisfying a service is, as well as meeting certain standards. Quality of care means providing treatment that benefits patients without harming them using tested methods. Accreditation involves an external review to ensure healthcare organizations comply with NABH standards. NABH has 10 chapters and over 100 standards covering both patient-centered and organization-centered areas like access to care, patient rights, infection control, and management responsibilities. Benefits of NABH accreditation include improved health outcomes, client and staff satisfaction, and a better reputation for healthcare institutions
The document discusses IRDA (Insurance Regulatory and Development Authority) and TPAs (Third Party Administrators). It provides details on IRDA's role in regulating the insurance sector in India, its mission and composition. It also outlines guidelines issued by IRDA on standardization in health insurance policies. The document then discusses the role of TPAs as intermediaries between insurers and insured, facilitating cashless services. It provides eligibility criteria for TPAs and the application process for obtaining a TPA license from IRDA. Benefits of TPAs for both insured and insurers are highlighted.
The Jan Aushadhi scheme launched by the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Govt. of India aims to make available quality generic medicines at affordable prices to all through special outlet known as Jan Aushadhi store opened/to be opened in each district of all the States. The new business plan approved by the Department of Pharmaceuticals in August, 2013 brought out it no. of changes to make the campaign a real success.
The Therapeutic Goods Administration (TGA) is a unit of the Australian Government Department of Health and Ageing that regulates therapeutic goods including medicines and medical devices. The TGA ensures these goods available in Australia meet acceptable standards of quality, safety and efficacy through a risk-based regulatory framework. It has over 700 staff from varied backgrounds including pharmacists, scientists, and medical officers. The TGA operates under the Therapeutic Goods Act of 1989 to provide a national framework for regulating therapeutic goods and maintains the Australian Register of Therapeutic Goods which lists goods approved for supply or export from Australia.
There are several issues with Sri Lanka's human resources for health including shortages of specialists and allied health professionals, lack of coordination between HRH producers and users, migration of health workers, and maldistribution of doctors and health professionals across provinces. Proposed policy changes include establishing a dedicated HRH unit to coordinate workforce planning and set targets, providing improved training for allied health professionals, and implementing incentives to retain health workers in rural areas.
Ranbaxy is India's largest pharmaceutical company, producing generic medicines for over 125 countries. It was founded in 1961 and went public in 1973. Ranbaxy has a global footprint with manufacturing facilities in 8 countries and offices in 43 countries. In 2008, Ranbaxy entered an alliance with Daiichi Sankyo to create an innovator and generic pharmaceutical powerhouse, now ranking among the top 20 pharmaceutical companies globally. Ranbaxy's mission is to enrich lives globally with quality and affordable pharmaceuticals.
The Drugs and Cosmetics Act of 1940 and its subsequent amendments aim to regulate and ensure safety and quality of drugs and cosmetics in India. Key provisions include licensing requirements for import, manufacture, and sale of drugs and cosmetics. The act establishes regulatory bodies like the Drugs Technical Advisory Board and Drugs Control Committees. It defines terms like misbranded, adulterated, and spurious drugs and cosmetics. The schedules to the act and rules classify drugs based on their use and safety.
The document provides an overview of Japan's regulatory system for pharmaceutical products. It discusses the classification of medical products, the required licenses to manufacture and market products, and the roles of the Ministry of Health and Pharmaceuticals and Medical Devices Agency. It also summarizes regulations around clinical trials, marketing approval, pricing, manufacturing, advertising, packaging, patents, trademarks, and product liability.
Understanding the Medical device Single Audit Program (MDSAP) & How to Prepar...Greenlight Guru
The Medical Device Single Audit Program (MDSAP) is an international initiative spearheaded by the International Medical Device Regulatory Forum (IMDRF) to develop a standardized global approach to auditing and inspecting of medical device manufacturers that will be accepted by multiple regulators to address QMS/GMP requirements.
Although the program has seen relatively low participation to date, the promise to help reduce compliance cost for device makers by eliminating the need for multiple quality system audits and inspections means there is much to be gained by industry from a successful implementation the program.
This presentation will cover:
-Understand the goals and benefits of the MDSAP program
-What are the main differences between MDSAP and standard auditing
-How to benchmark your QMS against the MDSAP
-How the new non-conformance grading system works
-How to prepare your company for a successful MDSAP implementation
Watch the presentation here: https://www.greenlight.guru/webinar/medical-device-single-audit-program-mdsap
regulatory requirnment and approval procedure for drugs and cosmetics, medica...sandeep bansal
This document outlines the regulatory requirements and approval procedures for drugs, cosmetics, medical devices, biological products, herbal medicines, and foods/nutraceuticals in India. It discusses the key regulatory bodies like the Central Drugs Standard Control Organization (CDSCO) and the application processes. For drugs, the new drug approval procedure is described involving applying to the DCGI and undergoing clinical trials and reviews. For other products, the document explains the application forms and documents required for approval from bodies like FSSAI.
Este documento presenta el plan de estudios de la carrera de Técnico de Laboratorio Clínico, incluyendo las fechas y temas de las clases de Salud Pública durante el año 2013. Explica brevemente el rol del Técnico de Laboratorio y la importancia de estudiar Salud Pública en esta carrera. También resume la evolución histórica de los conceptos de salud y enfermedad, las funciones de la OMS y OPS, y las definiciones modernas de salud adoptadas por la OMS.
This presentation provides an overview of nutraceuticals, including definitions of key terms like nutraceuticals and dietary supplements. It discusses examples of nutraceutical products like vitamins, minerals, metabolites, herbs and proteins/amino acids. The presentation also outlines the competitive nutraceutical landscape and provides statistics on the size of the Indian nutraceutical industry, projected to reach $4.4 billion by 2023. It directs attendees to additional resources on nutraceuticals from the primaryinfo.com website.
Fundamental knowledge on pharmaceutical
product development and translation from laboratory to market.
Quality management systems: Quality management & Certifications.
Si x sigma concepts.
Aim of 6 sigma concepts.
Process of 6 sigma concepts.
The Clinical Establishments (Registration & Regulation) Act mithun kherdemithun.kherde
The document discusses the history and need for regulation of clinical establishments in India. It outlines key constitutional provisions related to public health and various laws enacted over time to regulate medical professionals and institutions. The Clinical Establishments Act of 2010 was enacted to address ongoing issues of inadequate oversight and create a uniform system for registration, minimum standards, and monitoring of all clinical establishments across India. The Act established mechanisms like the National and State Councils for Clinical Establishments and District Registering Authorities to classify, register, and ensure compliance of healthcare facilities.
The document outlines a presentation on Schedule Y, which regulates clinical trials in India. It discusses the history of drug regulation in India, the key provisions of Schedule Y, and recent amendments made to Schedule Y. Some of the major changes include new definitions for clinical trials and new drugs, as well as additional regulation for special patient populations and post-marketing surveillance. The presentation provides an overview of Schedule Y and the rules governing clinical research in India.
This document contains opinions from Dr. Rajive K. Dikshit on various healthcare bills and policies in India. Some key points:
1) It opposes the National Commission for Human Resources in Health Bill, arguing it will centralize power and remove autonomy of existing councils.
2) It argues mandatory rural service after internship should only apply to graduates of government colleges and be optional for private colleges.
3) It stresses the need to improve facilities and pay for doctors in rural areas to attract them, rather than force compulsory service.
This document discusses quality and accreditation in hospitals in India. It provides information on:
1) What NABH is and its organizational structure, including its technical committee, accreditation committee, appeals committee and secretariat.
2) NABH's accreditation standards, which have 10 chapters covering 102 standards and 636 objectives.
3) The NABH accreditation process, including self-assessment, pre-assessment, final assessment, and the criteria hospitals are assessed against.
4) Consequences for hospitals like inactive status, shifting renewal dates, abeyance, suspension and withdrawal of accreditation if they do not meet requirements.
This document provides a checklist of documents required for obtaining market authorization in various BRICS countries. It introduces BRICS as an emerging market comprising Brazil, Russia, India, China and South Africa. Reasons for the emergence of BRICS markets include declining growth in developed markets and availability of patient populations in emerging markets. The checklist then outlines the documents required for market authorization from the regulatory authorities in India, China, South Africa and other BRICS countries. These include application forms, composition details, clinical trial reports, GMP certificates, and other product-specific documents.
Dear Students
We can help you to write total dissertation/project report.
Our 9 step method of project writing:-
Step 1) Helping you in Selection of topic.
Step 2) Group discussion / conference call with in team of professors.
Step 3) Helping you in Preparation of Synopsis/ proposal & sent to project guide
The document discusses NABH (National Accreditation Board for Hospitals and Healthcare Providers), which sets standards for quality healthcare in India. It establishes that quality refers to how good or satisfying a service is, as well as meeting certain standards. Quality of care means providing treatment that benefits patients without harming them using tested methods. Accreditation involves an external review to ensure healthcare organizations comply with NABH standards. NABH has 10 chapters and over 100 standards covering both patient-centered and organization-centered areas like access to care, patient rights, infection control, and management responsibilities. Benefits of NABH accreditation include improved health outcomes, client and staff satisfaction, and a better reputation for healthcare institutions
The document discusses IRDA (Insurance Regulatory and Development Authority) and TPAs (Third Party Administrators). It provides details on IRDA's role in regulating the insurance sector in India, its mission and composition. It also outlines guidelines issued by IRDA on standardization in health insurance policies. The document then discusses the role of TPAs as intermediaries between insurers and insured, facilitating cashless services. It provides eligibility criteria for TPAs and the application process for obtaining a TPA license from IRDA. Benefits of TPAs for both insured and insurers are highlighted.
The Jan Aushadhi scheme launched by the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Govt. of India aims to make available quality generic medicines at affordable prices to all through special outlet known as Jan Aushadhi store opened/to be opened in each district of all the States. The new business plan approved by the Department of Pharmaceuticals in August, 2013 brought out it no. of changes to make the campaign a real success.
The Therapeutic Goods Administration (TGA) is a unit of the Australian Government Department of Health and Ageing that regulates therapeutic goods including medicines and medical devices. The TGA ensures these goods available in Australia meet acceptable standards of quality, safety and efficacy through a risk-based regulatory framework. It has over 700 staff from varied backgrounds including pharmacists, scientists, and medical officers. The TGA operates under the Therapeutic Goods Act of 1989 to provide a national framework for regulating therapeutic goods and maintains the Australian Register of Therapeutic Goods which lists goods approved for supply or export from Australia.
There are several issues with Sri Lanka's human resources for health including shortages of specialists and allied health professionals, lack of coordination between HRH producers and users, migration of health workers, and maldistribution of doctors and health professionals across provinces. Proposed policy changes include establishing a dedicated HRH unit to coordinate workforce planning and set targets, providing improved training for allied health professionals, and implementing incentives to retain health workers in rural areas.
The Therapeutic Goods Administration is the regulatory body for therapeutic goods in Australia.he TGA is responsible for conducting assessment and monitoring activities to ensure that therapeutic goods available in Australia are of an acceptable standard and that access to therapeutic advances is in a timely manner.
Furnishing progressively an impeccable track record in providing outstanding healthcare facilities to the people of the entire capital city of India and especially the South- West Delhi incessant for the last 12 years, we announce with immense proud the launch of a new state of the art 150 bedded Multi & Super Specialty Hospital located at Sec – 10 in Dwarka, New Delhi. While possessing the most sophisticated technology and unsurpassable expertise across the entire spectrum of medical & surgical services we endeavor providing the most advanced services for the most affordable cost to as many as possible. This contains the finest combination of Medical, Surgical, Nursing and Technical support under the single roof.
The document discusses regulatory issues for Ayurveda, Siddha, and Unani (ASU) drugs in India. It outlines that the Drugs and Cosmetics Act of 1940 and Rules of 1945 regulate traditional medicines and require licensing for manufacturing. The Drug Technical Advisory Board (ASU DTAB) and Drug Consultative Committee (ASU DCC) advise the government on technical and regulatory matters related to ASU drugs. Their roles include recommending good manufacturing practices, reviewing pharmacopoeias, and ensuring uniform drug regulation across India.
The National Pharmaceutical Pricing Authority (NPPA) was established in 1997 by the Government of India to regulate drug prices. It fixes and revises the prices of controlled drugs and enforces them under the Drugs (Prices Control) Order. The NPPA monitors drug availability, shortages, production, imports/exports and ensures affordable prices of medicines in India. It collects data on drug companies and advises the government on drug policy matters.
The document discusses the Therapeutic Goods Administration (TGA) which regulates therapeutic goods in Australia. The TGA was established in 1990 to regulate medicines, medical devices, biologicals and other therapeutic goods. It evaluates products pre-market and monitors them post-market to ensure they meet standards of quality, safety and efficacy. The TGA uses a risk-based approach to regulation, with higher risk products facing more regulatory controls like prescription-only status. It works to align Australian regulations with international guidelines from places like the EU and US.
1. The document announces the 1st Annual Conference on Total Excipient Control hosted by IPEC India on July 21, 2016 in Mumbai.
2. IPEC India is the Indian chapter of the International Pharmaceutical Excipients Council (IPEC) Federation which promotes quality standards for excipients globally.
3. The conference aims to educate pharmaceutical professionals on Total Excipient Control and how it is important for ensuring quality, safety and efficacy of drugs in India and abroad. The agenda includes presentations and panels on excipient regulations, standards, and supply chain controls.
This presentation summarizes diagnostic services and healthcare strategies for effective performance. It discusses key drivers in the Indian diagnostic industry like foreign health insurance, relaxation in regulations, and emerging technologies. It profiles two major diagnostic service providers - Thyrocare Laboratories and Piramal Diagnostics. The presentation also analyzes in-house diagnostic services provided by Asian Heart Institute and Fortis Healthcare. It discusses their product offerings, pricing, promotion strategies, processes, and people. Lastly, it proposes strategies like focusing on patients, credibility, expertise, and accessibility to improve performance in the fragmented and competitive diagnostic market in India.
This document discusses the role of pharmacists in drug regulatory affairs in India. It provides an overview of the various drug regulatory authorities and committees in India, including the Central Drugs Standard Control Organization (CDSCO), Drug Technical Advisory Board (DTAB), and Drugs Consultative Committee (DCC). It also outlines some of the key regulations under the Drugs and Cosmetics Act, including licensing requirements for manufacturing, importing, and distributing drugs. Pharmacists can work in areas like quality control, quality assurance, regulatory affairs, and other roles for the pharmaceutical industry and drug regulatory agencies.
Ruth Skinner-Smith has over 30 years of experience in clinical nursing, management, and telehealth roles. She has worked in both Australia and the UK in hospitals, private clinics, and for telehealth companies. Her experience includes business development, clinical governance, project management, quality assurance, and remote patient monitoring via telehealth systems. Currently, she is seeking new opportunities in clinical management, telehealth, or related fields.
Presentation given to Pharmacy Technician students on career profiles: Aseptic Unit- Jennifer O\'Meara, Ward ased Technician (WBT) - Caroline McLoughlin, Clinical Trials - Sharon Curran-Rae & Purchasing - Yvonne Sheehan
The document provides an overview of medical device regulations from various regulatory agencies around the world. It discusses the purpose of regulations to control human behavior and ensure safety outcomes. Key regulatory agencies discussed include the TGA, FDA, PMDA, and EU, outlining their missions to protect public health through regulatory excellence and appropriate controls. A regulatory framework hierarchy is presented from laws to standards to guidance. Classification determines the extent of control and conformity assessments required. Cochlear implant systems are classified differently by various agencies. The key regulations governing Cochlear are also listed.
Medical Devices , regulations and e health solutionsshashi sinha
Medical Devices are now regulated in India. It is essential to know about the Medical Devices Regulations and how it is being implemented. Must know for all the manufacturers, importers and Distributors of Medical Devices.
Hi, everyone i am providing you the best presentation about the Pakistan relate Drug regulatory affairs and the concept of regulatory affairs of Pharmaceuticals
The document discusses various drug regulatory authorities around the world including the FDA, TGA, CDSCO, and ICMR. It provides an overview of the roles and responsibilities of these agencies in regulating drugs and pharmaceutical products to ensure public health and safety. Key functions of regulatory authorities that are described include evaluating new drugs, inspecting manufacturing facilities, monitoring adverse events, and establishing product standards.
Alejandro Kohn Tuli is a Chief Medical Officer with extensive experience in infrastructure development, quality improvement, and organizational support. He has held leadership roles at several hospitals in Qatar and Argentina, directing the implementation of electronic medical records systems and quality improvement programs. His background includes positions as Head of Cardiothoracic ICU, Director of Thoracic Surgery, and involvement in hospital accreditation and licensing.
The document summarizes China's regulatory system for food and health claims. It describes the various government agencies that oversee different aspects of food safety and standards. It also classifies different types of claims for foods and outlines the scientific evidence and testing required for functional and risk reduction claims. Regulations require health foods to be safe and improve physiological functions without treating diseases. Authorities evaluate claims and products to ensure they meet standards before approval.
The document provides an overview of drug regulatory affairs. It discusses how regulatory affairs developed to protect public health by controlling drug safety and efficacy. Regulatory affairs experts play an important role in managing a product's life cycle and ensuring compliance with laws and regulations. They act as a liaison between companies and regulatory bodies like CDSCO. Key responsibilities include assisting with licensing, registrations, clinical trials and maintaining required documents. The document also outlines some of the major acts governing drug regulation in India like the Drugs and Cosmetics Act.
Andreas Schleicher presents PISA 2022 Volume III - Creative Thinking - 18 Jun...EduSkills OECD
Andreas Schleicher, Director of Education and Skills at the OECD presents at the launch of PISA 2022 Volume III - Creative Minds, Creative Schools on 18 June 2024.
Gender and Mental Health - Counselling and Family Therapy Applications and In...PsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
🔥🔥🔥🔥🔥🔥🔥🔥🔥
إضغ بين إيديكم من أقوى الملازم التي صممتها
ملزمة تشريح الجهاز الهيكلي (نظري 3)
💀💀💀💀💀💀💀💀💀💀
تتميز هذهِ الملزمة بعِدة مُميزات :
1- مُترجمة ترجمة تُناسب جميع المستويات
2- تحتوي على 78 رسم توضيحي لكل كلمة موجودة بالملزمة (لكل كلمة !!!!)
#فهم_ماكو_درخ
3- دقة الكتابة والصور عالية جداً جداً جداً
4- هُنالك بعض المعلومات تم توضيحها بشكل تفصيلي جداً (تُعتبر لدى الطالب أو الطالبة بإنها معلومات مُبهمة ومع ذلك تم توضيح هذهِ المعلومات المُبهمة بشكل تفصيلي جداً
5- الملزمة تشرح نفسها ب نفسها بس تكلك تعال اقراني
6- تحتوي الملزمة في اول سلايد على خارطة تتضمن جميع تفرُعات معلومات الجهاز الهيكلي المذكورة في هذهِ الملزمة
واخيراً هذهِ الملزمة حلالٌ عليكم وإتمنى منكم إن تدعولي بالخير والصحة والعافية فقط
كل التوفيق زملائي وزميلاتي ، زميلكم محمد الذهبي 💊💊
🔥🔥🔥🔥🔥🔥🔥🔥🔥
CapTechTalks Webinar Slides June 2024 Donovan Wright.pptxCapitolTechU
Slides from a Capitol Technology University webinar held June 20, 2024. The webinar featured Dr. Donovan Wright, presenting on the Department of Defense Digital Transformation.
Leveraging Generative AI to Drive Nonprofit InnovationTechSoup
In this webinar, participants learned how to utilize Generative AI to streamline operations and elevate member engagement. Amazon Web Service experts provided a customer specific use cases and dived into low/no-code tools that are quick and easy to deploy through Amazon Web Service (AWS.)
Level 3 NCEA - NZ: A Nation In the Making 1872 - 1900 SML.pptHenry Hollis
The History of NZ 1870-1900.
Making of a Nation.
From the NZ Wars to Liberals,
Richard Seddon, George Grey,
Social Laboratory, New Zealand,
Confiscations, Kotahitanga, Kingitanga, Parliament, Suffrage, Repudiation, Economic Change, Agriculture, Gold Mining, Timber, Flax, Sheep, Dairying,
How to Download & Install Module From the Odoo App Store in Odoo 17Celine George
Custom modules offer the flexibility to extend Odoo's capabilities, address unique requirements, and optimize workflows to align seamlessly with your organization's processes. By leveraging custom modules, businesses can unlock greater efficiency, productivity, and innovation, empowering them to stay competitive in today's dynamic market landscape. In this tutorial, we'll guide you step by step on how to easily download and install modules from the Odoo App Store.
Elevate Your Nonprofit's Online Presence_ A Guide to Effective SEO Strategies...TechSoup
Whether you're new to SEO or looking to refine your existing strategies, this webinar will provide you with actionable insights and practical tips to elevate your nonprofit's online presence.
1. ISO 9001 Certified Organisation
TAMIL NADU MEDICAL SERVICES CORPORATION LTD
417 - IInd Floor, Pantheon Road, Egmore, Chennai – 600 008.
Phone : 28190259 / 28191890 / 28191891 Fax : 044 – 28190636
Email : enquiry@tnmsc.com
Website : www.tnmsc.com / http://tnmsc.tn.nic.in
TAMIL NADU MEDICAL SERVICES CORPORATION LTD
417 - IInd Floor, Pantheon Road, Egmore, Chennai – 600 008.
Phone : 28190259 / 28191890 / 28191891 Fax : 044 – 28190636
Email : enquiry@tnmsc.com
Website : www.tnmsc.com / http://tnmsc.tn.nic.in
2. Quality PolicyQuality Policy
Tamil Nadu Medical Services Corporation Limited supports the Government MedicalTamil Nadu Medical Services Corporation Limited supports the Government Medical
Institutions in providing quality health care delivery system to the people of Tamil NaduInstitutions in providing quality health care delivery system to the people of Tamil Nadu..
We arrange to deliver on time high quality drugs, medicines, surgical and suture itemsWe arrange to deliver on time high quality drugs, medicines, surgical and suture items
to the Government Medical Institutions with courtesy and care for our customers.to the Government Medical Institutions with courtesy and care for our customers.
To achieve this objective we adopt a rational drug management system, abiding by theTo achieve this objective we adopt a rational drug management system, abiding by the
applicable laws of the land and other regulatory requirements pertaining to the drugsapplicable laws of the land and other regulatory requirements pertaining to the drugs
and medicines.and medicines.
We achieve our goal with involvement and empowerment of our personnel throughWe achieve our goal with involvement and empowerment of our personnel through
continually improving a Quality Management System established in accordance withcontinually improving a Quality Management System established in accordance with
ISO 9001:2000.ISO 9001:2000.
3. ProfileProfile
Tamilnadu medical services corporation ltd..,(TNMSC)Tamilnadu medical services corporation ltd..,(TNMSC)
was incorporated under the Companies Act,1956 onwas incorporated under the Companies Act,1956 on
1/7/1994.1/7/1994.
It has commenced its functions of purchase,storageIt has commenced its functions of purchase,storage
and distribution of drugs and medicines from Januaryand distribution of drugs and medicines from January
1995.1995.
Its primary objective is to ensure ready availability ofIts primary objective is to ensure ready availability of
quality drugs and medicines in the Govt.Medicalquality drugs and medicines in the Govt.Medical
Institutions throughout the state.Institutions throughout the state.
4. BOARD OF DIRECTORSBOARD OF DIRECTORS
Chairman, TNMSC Ltd.,Chairman, TNMSC Ltd.,
Secretary, Health & Family Welfare DepartmentSecretary, Health & Family Welfare Department
Special Secretary, Finance DepartmentSpecial Secretary, Finance Department
Managing Director, TNMSC Ltd.,Managing Director, TNMSC Ltd.,
Project Director, Reproductive & Child Health ProjectProject Director, Reproductive & Child Health Project
Director of Medical EducationDirector of Medical Education
Director of Medical and Rural Health ServicesDirector of Medical and Rural Health Services
Director of Public Health & Preventive MedicineDirector of Public Health & Preventive Medicine
Director, Drug Control DepartmentDirector, Drug Control Department
Chief Engineer, Public Work Department (Buildings)Chief Engineer, Public Work Department (Buildings)
5. Organogram
MANAGING
DIRECTOR
Chief Accounts Officer/
Company Secretary
Senior Regional
Manager
Manager
(Quality Control)
Superintending
Engineer
Accounts
Construction
Work
24 Drug WarehousesE D P
Administration
Manager
(Purchase)
Purchase of
Equipments
Maintenance
of Equipments
Maintenance
of CT & MRI
Scan
CHAIRMAN
8. Comparison Before andComparison Before and
After TNMSCAfter TNMSC
Purchase by Deans/JDs of thePurchase by Deans/JDs of the
hospitals through Open Tenderhospitals through Open Tender
Supply by dealersSupply by dealers
Supplies were made in bulkSupplies were made in bulk
quantities in loose form in bottles.quantities in loose form in bottles.
Effective Quality Control was notEffective Quality Control was not
possible as the quantity on everypossible as the quantity on every
purchase is low.purchase is low.
Quality deteriorationQuality deterioration
Purchase by TNMSC through openPurchase by TNMSC through open
Tender.Tender.
Supply by manufacturers / DirectSupply by manufacturers / Direct
importersimporters
Supplies are made in Strips/BlistersSupplies are made in Strips/Blisters
which is easy to handle.which is easy to handle.
Rigorous Quality control is done.Rigorous Quality control is done.
Each and every batch is tested.Each and every batch is tested.
No Quality deteriorationNo Quality deterioration
9. Different rates for the hospitalsDifferent rates for the hospitals
Payment to the supplier was donePayment to the supplier was done
from different sources.from different sources.
Rates are Higher.Rates are Higher.
Uniform rates for all the hospitals.Uniform rates for all the hospitals.
Payment from Single source.Payment from Single source.
Bulk Purchase – Rates areBulk Purchase – Rates are
competitive and Cheapercompetitive and Cheaper..
Comparison Before andComparison Before and
After TNMSCAfter TNMSC
10. Institutions Served by TNMSCInstitutions Served by TNMSC
All Medical Teaching InstitutionsAll Medical Teaching Institutions 4242
All District Head Quarters Hospital.All District Head Quarters Hospital. 2525
All Taluk Head Quarters Hospital. 240All Taluk Head Quarters Hospital. 240
All Primary Health Centers 1413All Primary Health Centers 1413
All Health Sub Centers 8682All Health Sub Centers 8682
All ESI Hospitals and Dispensaries 185All ESI Hospitals and Dispensaries 185
All TNEB medical facilitiesAll TNEB medical facilities 2828
All Panchayat Union DispensariesAll Panchayat Union Dispensaries 5151
All Police Medical Facilities.All Police Medical Facilities. 1010
Juvenile Homes.Juvenile Homes. 1010
Prison and Rehabilitation homes.Prison and Rehabilitation homes. 1111
Co-operative Sugar Factories.Co-operative Sugar Factories. 1818
Veterinary Institutions. 285Veterinary Institutions. 285
Transport Corporation Dispensaries.Transport Corporation Dispensaries. 1414
All Local body Medical facilities.All Local body Medical facilities. 4545
Total 11059Total 11059
11. Budget
- Government makes budget allotment to Heads of departments
every year
- Heads of departments distribute this budget allotment to the
institutions based on which passbook is issued for lifting the
drugs.
- Heads of departments deposit 90% of this budget in the P.D.
Account of TNMSC for the purchase of drugs.
- TNMSC withdraws this amount as and when required for making
payment to the suppliers.
- Heads of departments allocate 10% of budget allotment to the
institutions for local purchase.
12. Value of Medicines Purchased during 2003-2004
Rs. in Lakhs
1142
1289
9711
Drugs
Surgical &
Suture
Veterinary
TNMSC’s TransactionsTNMSC’s Transactions
271 – DRUGS271 – DRUGS
92 – SUTURES92 – SUTURES
63 – SURGICALS63 – SURGICALS
133 –133 –
VETERINARYVETERINARY
No. of ItemsNo. of Items
Total Value Rs. 12142 LakhsTotal Value Rs. 12142 Lakhs
13. DRUG COMMITTEEDRUG COMMITTEE
Drug Committee consists of the following members.Drug Committee consists of the following members.
•Managing Director, TNMSC Ltd.Managing Director, TNMSC Ltd.
•Director of Medical EducationDirector of Medical Education
•Director of Medical and Rural Health ServicesDirector of Medical and Rural Health Services
•Director of Public Health and Preventive MedicineDirector of Public Health and Preventive Medicine
•Director of Family WelfareDirector of Family Welfare
•Director of Drug ControlDirector of Drug Control
•Professors of MedicineProfessors of Medicine
•Professors of SurgeryProfessors of Surgery
14. Purchase ProcedurePurchase Procedure
Drug committee discuss and decide about theDrug committee discuss and decide about the
drugs to be purchaseddrugs to be purchased
TenderTender
ProcessingProcessing
Invite Tender throughInvite Tender through
Press and WebsitePress and Website
Receipt & openReceipt & open
TenderTender
Signing ofSigning of
Agreement with SecurityAgreement with Security
DepositDeposit
Cover A OpeningCover A Opening
L1 RateL1 Rate
MatchingMatching
L1 RateL1 Rate
ProcessingProcessing
Issue of TenderIssue of Tender
DocumentDocument
Inspection ofInspection of
Manufacture unitManufacture unit
Evaluation ofEvaluation of
SamplesSamples
Cover B OpeningCover B Opening
DrugsDrugs
SurgicalSurgical
SutureSuture
Blood BankBlood Bank
11
22
33
44 55
66
66
77
88
99
1010
Issue of PurchaseIssue of Purchase
OrderOrder
1111
15. Tender ProcessTender Process
Drug committee to finalise the list of items (EssentialDrug committee to finalise the list of items (Essential
Drug List) and quantity for tenderDrug List) and quantity for tender
Advertisements:-Advertisements:-
♣ National Dailies through D.I.P.R.National Dailies through D.I.P.R.
♣ WebsitesWebsites
♣ Trade Journal like Pharma pulse, IDMATrade Journal like Pharma pulse, IDMA
♣ Letters to Drugs Controllers & Pharma AssociationLetters to Drugs Controllers & Pharma Association
Issue and receipt of Tender DocumentsIssue and receipt of Tender Documents
Tender CoverTender Cover ““AA”” openingopening
Tender Committee.Tender Committee.
Scrutinizing TeamScrutinizing Team
Inspection of the manufacturing premises of newInspection of the manufacturing premises of new
tenderers in case of drugstenderers in case of drugs
Evaluation of surgical/sutures samples by ExpertsEvaluation of surgical/sutures samples by Experts
16. SALIENT FEATURES INSALIENT FEATURES IN
COVER ‘A’COVER ‘A’
Licence for the product quotedLicence for the product quoted
Minimum three years market standingMinimum three years market standing
for the drug issued by the licensingfor the drug issued by the licensing
authorityauthority
Minimum turn over of Rs. 35 lakhsMinimum turn over of Rs. 35 lakhs
Non conviction certificate for threeNon conviction certificate for three
yearsyears
GMP certificateGMP certificate
17. SALIENT FEATURES INSALIENT FEATURES IN
COVER ‘B’COVER ‘B’
Printed format for quoting the landed pricePrinted format for quoting the landed price
excluding Sales Tax.excluding Sales Tax.
Printed format to furnish the break up detailsPrinted format to furnish the break up details
of landed priceof landed price
The tenderer is strictly prohibited toThe tenderer is strictly prohibited to
change /alter specification or unit size in thechange /alter specification or unit size in the
printed formatprinted format
The rate per unit(landed price)will be theThe rate per unit(landed price)will be the
criteria for determining the L1 ratecriteria for determining the L1 rate
The manufacturing capacity for each item forThe manufacturing capacity for each item for
effecting supplies to the warehouses withineffecting supplies to the warehouses within
60 days shall be given in the printed format60 days shall be given in the printed format
The above details of rates and capacity shallThe above details of rates and capacity shall
be given in computer floppybe given in computer floppy
18. TENDER CONDITIONSTENDER CONDITIONS
The tablet and capsule shall have the logogram inThe tablet and capsule shall have the logogram in
addition to the logogram on the strips/outer labelsaddition to the logogram on the strips/outer labels
The cap of the bottle shall not have the name of theThe cap of the bottle shall not have the name of the
manufacturermanufacturer
Samples of supplies in each batch will be chosen forSamples of supplies in each batch will be chosen for
testingtesting
The supply should be commenced within 30 days andThe supply should be commenced within 30 days and
completed within 60 dayscompleted within 60 days
Liquidated damages will be levied for delayed supplyLiquidated damages will be levied for delayed supply
(0.5% per day subject to a maximum of 15%)(0.5% per day subject to a maximum of 15%)
If the product fails in quality test , the entire batch willIf the product fails in quality test , the entire batch will
be returned to the supplier.be returned to the supplier.
20. Drug DistributionDrug Distribution
TNMSCTNMSC
Head OfficeHead Office
Other InstitutionsOther Institutions
Medical InstitutionsMedical Institutions
Head of DeptHead of Dept
Ware HouseWare House
SupplierSupplier
Requirement
Requirement Requirement
Requirement
Purchase
O
rder
Purchase
O
rder
SuppliesSupplies
Supplies
Supplies
Indents
Indents
Issue of
Issue of
Passbooks
Passbooks
28. DEDUCTION FOR QUALITY FAILUREDEDUCTION FOR QUALITY FAILURE
If the product fails in quality test, the product will not be accepted andIf the product fails in quality test, the product will not be accepted and
returned to the supplier.returned to the supplier.
Even if the field samples taken by the Drug Inspector fails in qualityEven if the field samples taken by the Drug Inspector fails in quality
test the cost of the quantity remaining unutilized will be recovered fromtest the cost of the quantity remaining unutilized will be recovered from
the supplier apart from the levying of other penalties / punishmentsthe supplier apart from the levying of other penalties / punishments
including blacklisting.including blacklisting.
If there is any complaint from the Medical Officer about the quality ofIf there is any complaint from the Medical Officer about the quality of
the product the remaining quantity in the particular batch will be returnedthe product the remaining quantity in the particular batch will be returned
to the supplier and value equal to the quantity returned will be recovered.to the supplier and value equal to the quantity returned will be recovered.
29. PROCEDURE FORPROCEDURE FOR
BLACKLISTINGBLACKLISTING
• In case during the contract period the supplier fails to execute threeIn case during the contract period the supplier fails to execute three
consecutive purchase orders issued in full within 90 days then theconsecutive purchase orders issued in full within 90 days then the
product will be blacklisted for the firm after giving due opportunity theproduct will be blacklisted for the firm after giving due opportunity the
firm to explain the reason for the non execution of purchase orders.firm to explain the reason for the non execution of purchase orders.
• During the contract period if two batches of the particular itemDuring the contract period if two batches of the particular item
supplied by the firm fails in quality test (Assay content) the product ofsupplied by the firm fails in quality test (Assay content) the product of
that particular firm will be blacklisted.that particular firm will be blacklisted.
• During the contract period if three batches of the particular itemDuring the contract period if three batches of the particular item
supplied by the firm fails in quality test (description test and othersupplied by the firm fails in quality test (description test and other
parameters mentioned in pharmocopeia / As per IS specification) thenparameters mentioned in pharmocopeia / As per IS specification) then
that particular item will be blacklisted for the firm.that particular item will be blacklisted for the firm.
• In respect of the firm supplying more than one item during theIn respect of the firm supplying more than one item during the
contract period if more than 50% of the items are blacklisted based oncontract period if more than 50% of the items are blacklisted based on
the above process then the firm will be blacklisted.the above process then the firm will be blacklisted.
30.
Description 98-99 99-2000 2000-01 2001-02 2002-03
No. of Samples Sent to QC Lab 10065 10185 10476 11065 12012
No. of Samples Passed 9736 9874 10186 10824 11844
No. of Samples Failed 329 311 290 241 168
% Passed 96.73 96.94 97.23 97.82 98.60
% of Failure 3.26 3.05 2.76 2.17 1.40
Assessment of Samples Sent for QC TestAssessment of Samples Sent for QC Test
2003-04
14778
14600
178
98.8
1.20
31. Management InformationManagement Information
System-MISSystem-MIS
• Exceptional Stock Statement
• Slow Moving Drug List
• Drug Order Statement
• Passbook Utilisation Report
• Unexecuted Order Statement
• Abstract Pending Bills Report
• Time Expiry Drugs
• Abstract Order & Supplied Value Report
32. Diagnostics ServicesDiagnostics Services
(i) ISO 9001:2000 certified GI Bleed and Hepatobiliary Centre(i) ISO 9001:2000 certified GI Bleed and Hepatobiliary Centre
(Special Ward) maintained by TNMSC is functioning as a(Special Ward) maintained by TNMSC is functioning as a
separate unit under the Surgical Gastroentrology Department inseparate unit under the Surgical Gastroentrology Department in
Government Stanley Hospital, Chennai.Government Stanley Hospital, Chennai.
(ii) TNMSC is maintaining the Master Health Checkup Scheme at(ii) TNMSC is maintaining the Master Health Checkup Scheme at
Government General Hospital, Chennai.Government General Hospital, Chennai.
(iii) TNMSC is maintaining the Special Class Maternity Ward in(iii) TNMSC is maintaining the Special Class Maternity Ward in
IOG, Chennai-8.IOG, Chennai-8.
(iv) TNMSC has provided infrastructure facilities to the payment(iv) TNMSC has provided infrastructure facilities to the payment
ward in Govt. Kasturba Gandhi Hospital, chennai-5 and startedward in Govt. Kasturba Gandhi Hospital, chennai-5 and started
maintaining the same from 03-05-2004.maintaining the same from 03-05-2004.
33. TNMSC CT Scan CenterTNMSC CT Scan Center
TNMSC is maintaining 36 CT Scan Centres inTNMSC is maintaining 36 CT Scan Centres in
Govt. Hospitals.Govt. Hospitals.
The following charges are collected for scanning.The following charges are collected for scanning.
Category Plain With ContrastCategory Plain With Contrast
Inpatients Rs. 350/- Rs. 550/-Inpatients Rs. 350/- Rs. 550/-
Outpatients Rs. 500/- Rs. 700/-Outpatients Rs. 500/- Rs. 700/-
34. TNMSC MRI Scan CenterTNMSC MRI Scan Center
TNMSC is maintaining 1.5 Tesla MRI atTNMSC is maintaining 1.5 Tesla MRI at
- Govt. General Hospital, Chennai.- Govt. General Hospital, Chennai.
- Govt. Rajaji Hospital, Madurai.- Govt. Rajaji Hospital, Madurai.
CategoryCategory PlainPlain With ContrastWith Contrast
Larger PartsLarger Parts Rs. 3500/- EachRs. 3500/- Each Rs. 5000/- EachRs. 5000/- Each
Smaller PartsSmaller Parts Rs. 2500/- EachRs. 2500/- Each Rs. 4000/- EachRs. 4000/- Each
35. Purchase and Supply ofPurchase and Supply of
equipments to hospitalsequipments to hospitals
TNMSC has finalized rate contract (CPC System) through openTNMSC has finalized rate contract (CPC System) through open
tender for the purchase of equipments & accessories required fortender for the purchase of equipments & accessories required for
19 departments in Government hospitals consisting of about 307819 departments in Government hospitals consisting of about 3078
items for the period 2002-2004. The medical institutions canitems for the period 2002-2004. The medical institutions can
directly place purchase orders with the approved firms for thedirectly place purchase orders with the approved firms for the
supply of required equipments and accessories at the approvedsupply of required equipments and accessories at the approved
rates depending upon the budget provision.rates depending upon the budget provision.
The medical equipments required for the governmentThe medical equipments required for the government
hospitals are procured and supplied by TNMSC based onhospitals are procured and supplied by TNMSC based on
the Government order issued for this purpose from time tothe Government order issued for this purpose from time to
timetime
36. Construction Activities ofConstruction Activities of
TNMSCTNMSC
(i) Implementation of World Bank Assisted RCH Project(i) Implementation of World Bank Assisted RCH Project
Under this project, construction of Buildings for 8 UHPs and 21 HSCs andUnder this project, construction of Buildings for 8 UHPs and 21 HSCs and
improvement works in 35 PHCs and 70 HSCs for Rs.5.65 Crores have beenimprovement works in 35 PHCs and 70 HSCs for Rs.5.65 Crores have been
completed by TNMSC in Madurai & Theni Districts.completed by TNMSC in Madurai & Theni Districts.
(ii) Regional Diagnostic Centres(ii) Regional Diagnostic Centres
TNMSC has established 7 Regional Diagnostic centres in the State (BuildingTNMSC has established 7 Regional Diagnostic centres in the State (Building
and Equipment) at Thiruvannamalai, Villupuram, Pudukottai, Virudhunagar,and Equipment) at Thiruvannamalai, Villupuram, Pudukottai, Virudhunagar,
Ramanathapuram, Nammakkal and Tiruppur at a total cost of Rs.21.00 CroresRamanathapuram, Nammakkal and Tiruppur at a total cost of Rs.21.00 Crores
funded by the Government of India.funded by the Government of India.
(iii) Accident and Emergency Ward (Trauma Care Centre)(iii) Accident and Emergency Ward (Trauma Care Centre)
Construction and procurement of equipments for the Accident and EmergencyConstruction and procurement of equipments for the Accident and Emergency
ward at Ambur, Krishnagiri, Tindivanam, Sriperumbudur and Kovilpatti have beenward at Ambur, Krishnagiri, Tindivanam, Sriperumbudur and Kovilpatti have been
completed at a cost of Rs.2.93 Crores provided by the Home Department.completed at a cost of Rs.2.93 Crores provided by the Home Department.
37. Consultancy ServicesConsultancy Services
TNMSC is a Role Model for other states of India onTNMSC is a Role Model for other states of India on
Drug Logistics and Warehousing.Drug Logistics and Warehousing.
TNMSC has taken up and completed the consultancyTNMSC has taken up and completed the consultancy
project for the preparation of Feasibility report forproject for the preparation of Feasibility report for
Andhra Pradesh.Andhra Pradesh.
Govt. of Rajasthan has entrusted preparation ofGovt. of Rajasthan has entrusted preparation of
feasibility report to TNMSC. Draft Final reportfeasibility report to TNMSC. Draft Final report
submitted to Govt. of Rajasthan.submitted to Govt. of Rajasthan.
Training course on Drug Logistics and WarehousingTraining course on Drug Logistics and Warehousing
has been conducted for Pharmacists, H & FWhas been conducted for Pharmacists, H & FW
department , Govt. of Karnataka during May 2003department , Govt. of Karnataka during May 2003
and for Pharmacists, H & FW department , Govt. ofand for Pharmacists, H & FW department , Govt. of
Assam during June 2004.Assam during June 2004.